Curaleaf Holdings Inc banner

Curaleaf Holdings Inc
TSX:CURA

Watchlist Manager
Curaleaf Holdings Inc Logo
Curaleaf Holdings Inc
TSX:CURA
Watchlist
Price: 4.77 CAD 6.47% Market Closed
Market Cap: CA$3.7B

EV/IC

1.3
Current
28%
More Expensive
vs 3-y average of 1

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.3
=
Enterprise Value
CA$3.7B
/
Invested Capital
$2.7B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.3
=
Enterprise Value
CA$3.7B
/
Invested Capital
$2.7B

Valuation Scenarios

Curaleaf Holdings Inc is trading above its 3-year average

If EV/IC returns to its 3-Year Average (1), the stock would be worth CA$3.73 (22% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-22%
Maximum Upside
+114%
Average Upside
26%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1.3 CA$4.77
0%
3-Year Average 1 CA$3.73
-22%
5-Year Average 1.2 CA$4.46
-7%
Industry Average 2.7 CA$10.21
+114%
Country Average 1.5 CA$5.57
+17%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
US
Curaleaf Holdings Inc
TSX:CURA
3.7B CAD 1.3 -11.5
US
Eli Lilly and Co
NYSE:LLY
910.2B USD 9.4 44.1
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 3.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 2.9 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 3.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 2.9 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 2.6 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 56 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 2.7 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 1 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
117.2B USD 2 16.6
P/E Multiple
Earnings Growth PEG
US
Curaleaf Holdings Inc
TSX:CURA
Average P/E: 22.4
Negative Multiple: -11.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.1
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

In line with most companies in the United States of America
Percentile
44th
Based on 11 657 companies
44th percentile
1.3
Low
0 — 0.9
Typical Range
0.9 — 2.9
High
2.9 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 0.9
Median 1.5
70th Percentile 2.9
Max 566 432.7

Curaleaf Holdings Inc
Glance View

Curaleaf Holdings Inc., a prominent player in the burgeoning cannabis market, has carved out a significant niche for itself by fully integrating its operations from cultivation to distribution. Founded in 2010, the Massachusetts-based company has rapidly grown to become one of the largest cannabis retailers in the United States. With a keen eye on the complex regulatory landscape, Curaleaf has strategically expanded its footprint across multiple states, adapting to various state laws and regulations. Their operational strategy hinges on vertical integration, meaning they control every stage of the cannabis supply chain. This allows Curaleaf not only to maintain high product quality and consistency but also to maximize margins by reducing costs and gaining efficiencies at all levels of production and retailing. Generating revenue through a combination of wholesale and retail sales, Curaleaf has established a range of products including cannabis flower, oils, edibles, and topical treatments, catering to both medical and recreational customers. The company's retail outlets, spanning across multiple states, are crucial in driving sales, where knowledgeable staff guide customers through intricate product offerings aimed at satisfying diverse consumer needs. Meanwhile, Curaleaf’s wholesale division supplies products to other retail outlets, expanding its market reach and solidifying its brand presence. The synergy between its retail prowess and wholesale operations has allowed Curaleaf to sustain steady revenue growth, positioning it well in a highly competitive and rapidly evolving industry.

CURA Intrinsic Value
2.74 CAD
Overvaluation 42%
Intrinsic Value
Price CA$4.77
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett